129 related articles for article (PubMed ID: 38678485)
1. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38678485
[TBL] [Abstract][Full Text] [Related]
2. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study.
Cai H; Chen S; Wu Z; Wang F; Tang S; Chen L; Guo W
J Hepatocell Carcinoma; 2024; 11():399-409. PubMed ID: 38435682
[TBL] [Abstract][Full Text] [Related]
4. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Atezolizumab Plus Bevacizumab and Hepatic Artery Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter, Propensity Score Study.
Kim JH; Nam HC; Kim CW; Cho HS; Yoo JS; Han JW; Jang JW; Choi JY; Yoon SK; Yang H; Bae SH; Kim S; Oh JS; Chun HJ; Jeon CH; Ahn J; Sung PS
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686509
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
[TBL] [Abstract][Full Text] [Related]
9. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
11. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
12. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
[TBL] [Abstract][Full Text] [Related]
13. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K; Morishita A; Manabe T; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Ono M; Ogawa C; Moriya A; Senoo T; Tsutsui A; Nagano T; Takaguchi K; Himoto T; Masaki T
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370853
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
[TBL] [Abstract][Full Text] [Related]
16. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
[TBL] [Abstract][Full Text] [Related]
17. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang CL; Chan SK; Lee SF; Choi HC
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Kulkarni AV; Tevethia H; Kumar K; Premkumar M; Muttaiah MD; Hiraoka A; Hatanaka T; Tada T; Kumada T; Kakizaki S; Vogel A; Finn RS; Rao PN; Pillai A; Reddy DN; Singal AG
EClinicalMedicine; 2023 Sep; 63():102179. PubMed ID: 37680945
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.
Xin Y; Cao F; Yang H; Zhang X; Chen Y; Cao X; Zhou X; Li X; Zhou J
Front Immunol; 2022; 13():929141. PubMed ID: 35990634
[TBL] [Abstract][Full Text] [Related]
20. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.
Yu Q; Wang Y; Ungchusri E; Patel M; Kumari D; Van Ha T; Pillai A; Liao CY; Ahmed O
J Interv Med; 2023 Nov; 6(4):187-193. PubMed ID: 38312131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
